MedTrace Logo

A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)

NCT02912494 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2019-04-02

No results posted yet for this study

Summary

The purpose of this study is to investigate the equivalence of JR-131 to Darbepoetin alfa and evaluate the safety of JR-131 in renal anemia patients with chronic kidney disease (CKD).

Conditions

Interventions

DRUG

JR-131

DRUG

Darbepoetin alfa

Sponsors & Collaborators

  • JCR Pharmaceuticals Co., Ltd.

    collaborator INDUSTRY

  • Kissei Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Masking
DOUBLE

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-09-30
Completion
2017-09-30

Countries

  • Japan

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02912494 on ClinicalTrials.gov